Therapeutic strategies in B-cell Non-Hodgkins Lymphoma

Dr Bob Phillips
Leeds Children’s Hospital and Centre for Reviews and Dissemination
University of York
B-cell neoplasms

Predominantly small B-cells
- Indolent small B-cell lymphomas*

Blastic/blastoid-appearing B-cells
- MCL
- Precursor B-LBicL

Numerous intermediate-large transformed B-cells†
- DLBCL (variants and subtypes)
- Burkitt lymphoma
- BCL, high grade, NOS‡
The figure illustrates the survival rates of different types of lymphoma over time (in months). The X-axis represents time in months, ranging from 0.00 to 50.00. The Y-axis represents the proportion surviving, ranging from 0.0 to 1.0.

- **ALCL** (Anaplastic Large Cell Lymphoma) shows a high proportion surviving, indicating better outcomes.
- **Lymphoma intermediate between Burkitt's and DLBL** appears to have a moderate survival rate.
- **DLBL** (Diffuse Large B-Cell Lymphoma) shows a declining survival rate over time.
- **Burkitt's lymphoma** has the worst survival rate, with a rapid decrease in proportion surviving.
- **Lymphoblastic lymphoma** also has a poor survival rate, similar to Burkitt's lymphoma.

The graph uses different symbols and line styles to distinguish between the survival curves of these lymphoma types.
Group A

• Resected I
• Resected abdominal II

Group B

• All the rest

Group C

• CNS involved
• Marrow >25%
Event-free survival (%) vs. number at risk.

- Red line: R-CHEMO
- Blue line: CHEMO

Log-rank p < 0.0001
CD20-induced apoptosis

B lymphocyte

CD20

Rituximab

Apoptosis
② Classical complement activation

- B lymphocyte
- CD20
- Membrane attack complex (MAC)
- Rituximab
- Lysis
C3b opsonisation and phagocytosis

- C1
- B lymphocyte
- C3b
- CD20
- Rituximab
- Complement receptor

Phagocytosis

Phagocyte
IgG opsonisation and phagocytosis

- Rituximab
- CD20
- B lymphocyte
- Fc receptor
- Phagocytosis
- Phagocyte
Antibody-dependent cell cytotoxicity by natural killer cells
Dose-Adjusted EPOCH-R

- Years on Study
  - 0, 1, 2, 3, 4, 5, 6, 7, 8

- Percent Disease-Free
  - 0%, 20%, 40%, 60%, 80%, 100%
Therapeutic strategies in B-cell Non-Hodgkins Lymphoma

Dr Bob Phillips
bob.phillips@york.ac.uk